ArticleFrontiers in medicine2026
Optical coherence tomography features and visual prognosis in vitreoretinal lymphoma: a structured phenotyping study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize optical coherence tomography (OCT) features of vitreoretinal lymphoma (VRL) at baseline, identify features associated with visual prognosis, and describe longitudinal OCT changes following intravitreal methotrexate (IVT-MTX) treatment. Design: Retrospective, single-center, observational study. Methods: Consecutive biopsy-proven VRL cases were included. Spectral-domain OCT (SD-OCT) features were classified into three compartments: sub-retinal pigment epithelium (sub-RPE), subretinal, and intraretinal deposits. Additional features included ellipsoid zone (EZ) disruption, EZ-RPE attenuation, preretinal deposits, and vitreous cells. Patients were stratified as isolated VRL or VRL with concurrent central nervous system involvement (VRL-CNS). Best-corrected visual acuity (BCVA) was analyzed as a continuous variable (logMAR) using generalized estimating equations (GEE) with patient-level clustering, and an exploratory LASSO model was developed to predict significant vision loss (logMAR ≥ 0.5). A subgroup receiving standardized IVT-MTX with longitudinal OCT was analyzed across treatment phases. Results: Thirty-eight eyes of 25 patients (14 female; mean age 63.5 ± 12.6 years) were included over a median follow-up of 14.2 months. Sub-RPE deposits were the most prevalent OCT feature (92.1%), followed by subretinal deposits (65.8%) and intraretinal deposits (23.7%). In the multivariable GEE model, baseline BCVA ( Conclusion: Sub-RPE deposits are the most prevalent OCT finding in VRL. EZ disruption and EZ-RPE attenuation are associated with worse visual prognosis. Following IVT-MTX treatment, OCT reveals differential response patterns across lesion compartments, supporting quantitative OCT assessment as a sensitive, noninvasive tool for treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.